# DESCRIPTION

## FIELD OF THE INVENTION

- introduce soluble FGF decoy polypeptides

## BACKGROUND OF THE INVENTION

- describe FGFR3 and skeletal growth retardation disorders

## SUMMARY OF THE INVENTION

- introduce sFGFR3 decoy polypeptides
- describe fusion protein sFGF decoy polypeptide
- specify aggrecan-binding protein or fragment
- describe alternative heterologous polypeptide
- introduce nucleic acid encoding fusion protein
- outline methods of treatment using fusion protein

## Definitions

- define terminology
- specify scope of invention
- describe elements of invention
- define specific terms
- define decoy receptor
- define detectable label
- describe eukaryotic cell
- describe extracellular domain
- define FGFR3-related skeletal disease
- describe fibroblast growth factor
- describe fibroblast growth factor receptor 3
- define fragment
- define FGFR3 polypeptide fragment
- define fusion protein
- define idiopathic skeletal growth retardation disorder
- define monitoring
- define nucleic acid
- define peptide linker
- define pharmaceutically acceptable and polypeptide
- define prokaryotic cell
- define skeletal growth retardation disorder
- define soluble protein or polypeptide
- define soluble FGFR3 polypeptide
- define specifically binds
- define subject or patient
- define treat, treating, or treatment
- define variant and vector

## DETAILED DESCRIPTION OF THE INVENTION

- introduce soluble FGFR3 polypeptide variants for treating skeletal growth retardation disorders

### Fibroblast Growth Factor Receptor 3

- define FGFR3 polypeptides and nucleic acids encoding them
- describe FGFR3 polypeptides with specific amino acid sequences
- discuss FGFR3 isoforms and their encoding nucleic acids
- provide examples of FGFR3 polypeptides with specific functions
- describe FGFR3 polypeptides with deletions or mutations
- discuss FGFR3 polypeptides with specific binding affinities
- summarize FGFR3 polypeptides and their uses

### Methods of Treatment

- describe treatment of skeletal growth retardation disorders
- administer sFGFR3 polypeptide or fusion polypeptide
- treat symptoms of achondroplasia
- describe skeletal growth retardation disorders
- administer sFGFR3 polypeptide or fusion polypeptide to treat disorders
- describe symptoms of skeletal growth retardation disorders
- monitor symptoms of achondroplasia

### Pharmaceutical Compositions and Formulations

- describe administration methods
- outline dosage considerations
- provide dosage ranges
- discuss dosing regimens
- describe carriers/vehicles
- outline pharmaceutical forms
- discuss formulation considerations
- introduce gene therapy
- describe gene therapy methods

## EXAMPLES

### Example 1

- describe decoy design and testing procedures
- detail cloning and protein production system
- outline FGF binding and aggrecan binding assays
- summarize efficacy study in mice and evaluation of velocity of growth

### Example 2

- summarize in vitro testing of deletion variants

### Example 3

- summarize in vitro testing of Del4 deletion variant

### Example 4

- summarize in vitro testing of targeted decoy

### Example 5

- summarize in vivo testing of targeted decoy

### Conclusion

- summarize study results and conclusions

### Example 6

- describe decoy design and purification of sFGFR3 polypeptides and fusion polypeptides

### Example 7

- demonstrate role of signal sequence in sFGFR3 polypeptides and fusion polypeptides

### Example 8

- perform biodistribution treatment
- determine biodistribution of sFGFR3_Del1 and sFGFR3_Del4-LK1-LK2
- analyze effect on growth plate thickness and hypertrophic chondrocyte zone
- perform skull measurements and x-ray radiography
- analyze results of biodistribution and skull measurements

